You’re losing weight. The scale is finally moving. So why does it feel like it might not last?
This is part of Flow BioLabs’ Feel Better Now path — see the full guide →.
Here’s what most people on GLP-1s aren’t told until it’s too late: some of what you’re losing isn’t fat. It’s muscle. And muscle is the one thing standing between you and gaining it all back the moment you stop.
This is the trap. You lose weight fast, muscle goes with it, and muscle is what burns calories at rest — so your metabolism quietly slows. Then you come off the medication, appetite returns, and you’re carrying a slower engine into the exact conditions that made you gain weight before. It comes back. Often more than you lost.
You break that cycle by protecting the engine while the scale drops — not after. Here’s the research behind why that matters, and exactly what to do about it.
What actually happens when you stop a GLP-1
The clearest picture comes from the STEP 1 trial extension, published in Diabetes, Obesity and Metabolism. Researchers followed adults who had taken semaglutide 2.4 mg (the active ingredient in Wegovy) for 68 weeks, then stopped the medication and lifestyle support entirely and tracked them for another year. Participants had lost an average of 17.3% of their body weight while on treatment. One year after stopping, they had regained about two-thirds of it — roughly 11.6 percentage points back, versus almost no change in the group that had been on placebo the whole time (Wilding et al., 2022, STEP 1 extension). Blood pressure, blood sugar, cholesterol, and waist circumference improvements reversed right along with the weight.
A similar pattern showed up with tirzepatide (Zepbound/Mounjaro) in the SURMOUNT-4 trial. A 2026 post hoc analysis published in JAMA Internal Medicine found that most participants who had lost significant weight on tirzepatide and then had it withdrawn regained weight — and the more weight they regained, the more their waist size, blood pressure, and cholesterol markers moved back toward where they started (SURMOUNT-4 post hoc analysis, JAMA Internal Medicine, 2026). Researchers describe this as consistent with obesity being a chronic condition: the drugs work by suppressing appetite and slowing digestion while you’re on them, and when that mechanism is removed, the underlying drivers of weight gain are often still there.
Why muscle is the hidden variable
Weight regain isn’t only about appetite returning. It’s also about what kind of weight was lost in the first place. Body composition sub-studies of both semaglutide and tirzepatide trials, measured with DEXA scans (a precise bone-and-tissue density scan), found that lean soft tissue — muscle, organs, and connective tissue — accounted for roughly 26% to 40% of total weight lost on these medications. In the STEP 1 DEXA subset, participants lost about 6.9 kg of lean tissue alongside 10.4 kg of fat mass, meaning nearly 40% of their weight loss came from lean tissue rather than fat (lean tissue preservation case series, 2025, citing STEP 1 and SURMOUNT-1 DEXA data).
Here’s why that matters mechanically: muscle is metabolically active tissue. It’s a major driver of your resting metabolic rate — the calories your body burns just to keep running at rest. Lose a meaningful share of it, and your resting metabolic rate drops with it. So even if you go back to eating exactly what you ate before treatment, you’re now burning fewer calories doing the same things, which tilts the math toward regain. This is the “slower engine” problem: the body you have after rapid weight loss is not just smaller, it’s changed in ways that make it easier to regain fat specifically.
The encouraging finding, from the same body of research: this isn’t inevitable. A small case series in SAGE Open Medical Reports followed patients on semaglutide or tirzepatide who deliberately combined treatment with structured resistance training 3 to 5 days a week. Some of them preserved nearly all of their lean tissue — and two participants actually gained lean mass while still losing significant fat (case series, SAGE Open Medical Reports, 2025). The medication drives the calorie deficit; what you do with your muscles during that deficit determines what kind of weight you lose.
The three levers that actually matter
None of this requires a dramatic lifestyle overhaul. It requires attention to three specific things while you’re losing weight, not after.
- Anchor every meal to protein. Adequate protein intake gives your body the raw material it needs to maintain muscle even while you’re eating in a calorie deficit and appetite is suppressed. This matters more on a GLP-1, not less, because reduced hunger often means less total food and less protein unless you deliberately prioritize it.
- Strength-train, even lightly. Resistance exercise is the clearest signal you can send your body that muscle is still needed for daily demands, which is what determines whether the body preserves or sheds it during weight loss.
- Loop in a clinician on dosing and nutrition. The STEP and SURMOUNT extension data both point to the same conclusion: these medications treat a chronic condition, and stopping abruptly without a plan for maintenance — nutrition, activity, and possibly a tapering strategy — is when regain is most likely. The right plan is personal, and it should be built before you stop, not after the weight starts coming back.
You don’t need to overhaul your life today. You need the one next move that protects what matters. Find yours in 2 minutes.
FAQ
Do you regain all the weight after stopping a GLP-1 medication?
Not necessarily all of it, but research shows most people regain a substantial portion. In the STEP 1 extension trial, participants regained about two-thirds of the weight they’d lost within one year of stopping semaglutide, though they still retained some net loss compared to their starting weight (Wilding et al., 2022).
Why does muscle loss make weight regain worse?
Muscle tissue burns more calories at rest than fat tissue. When a meaningful share of weight loss comes from muscle rather than fat, your resting metabolic rate drops, meaning your body needs fewer calories to maintain the same weight — which makes it easier to regain fat once appetite and eating patterns return to normal.
Can you prevent muscle loss while on a GLP-1?
Evidence suggests yes, at least partially. Case reports show that people who combined GLP-1 treatment with consistent resistance training and adequate protein intake preserved significantly more lean tissue than typical trial averages, with some even gaining lean mass during treatment (SAGE Open Medical Reports, 2025).
Is it safe to stop a GLP-1 medication on your own?
Stopping without a maintenance plan is associated with significant weight and cardiometabolic regain in clinical trial data. Any decision to change dose or discontinue treatment is best made with a clinician who can help build a nutrition, activity, and monitoring plan around the transition.
→ Take the free Metabolic Friction Assessment
Looking for a different angle? Our Build Better Habits path — see the full guide → — may also be relevant.